Karin L. Walker - 18 Nov 2022 Form 4 Insider Report for PROTHENA CORP PUBLIC LTD CO (PRTA)

Role
Chief Accounting Officer
Signature
/s/ Michael Malecek, as Attorney in Fact for Karin L. Walker
Issuer symbol
PRTA
Transactions as of
18 Nov 2022
Net transactions value
-$420,309
Form type
4
Filing time
18 Nov 2022, 20:32:29 UTC
Previous filing
26 Oct 2022
Next filing
03 Mar 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PRTA Ordinary Shares, par value $0.01 per share Options Exercise $150,400 +10,000 $15.04* 10,000 18 Nov 2022 Direct
transaction PRTA Ordinary Shares, par value $0.01 per share Sale $557,539 -9,774 -98% $57.04 226 18 Nov 2022 Direct F1, F2
transaction PRTA Ordinary Shares, par value $0.01 per share Sale $13,170 -226 -100% $58.27 0 18 Nov 2022 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PRTA Stock Option (right to buy) Options Exercise $0 -10,000 -15% $0.000000 55,481 18 Nov 2022 Ordinary Shares 10,000 $15.04 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
F2 The transaction was executed in multiple trades in prices ranging from $56.39 to $57.34, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in footnotes 2 through 3 of this Form 4.
F3 The transaction was executed in multiple trades in prices ranging from $57.415 to $58.29, inclusive.
F4 The shares subject to the option vested and became exercisable as to 25% of the total number of shares subject to the option on June 21, 2019, and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.